A Phase I/II Study of the NT-501 Intraocular Implant Releasing Ciliary Neurotrophic Factor (CNTF) in Participants With CNGB3 Achromatopsia
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Revakinagene taroretcel (Primary)
- Indications Colour vision defects
- Focus Adverse reactions
- 30 Sep 2016 Status changed from active, no longer recruiting to completed.
- 06 Nov 2014 New trial record